\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesA total of 163 proposals were submitted to the 2024-01 research infrastructures calls with deadline 12 March 2024.
For the call HORIZON-INFRA-2024-TECH-01 Next generation of scientific instrumentation, tools, methods, and advanced digital solutions for RIs (2024) 69 proposals have been submitted. The breakdown per topic is:
For the call HORIZON-INFRA-2024-EOSC-01 Enabling an operational, open and FAIR EOSC ecosystem (2024) 22 proposals have been submitted. The breakdown per topic is:
For the call HORIZON-INFRA-2024-DEV-01 Developing, consolidating and optimising the European research infrastructures landscape, maintaining global leadership (2024) 72 proposals have been submitted. The breakdown per topic is:
Evaluation results are expected to be communicated in July 2024.
Source: European Commission Funding and tenders portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Culture and society Civil Security
More information is available about opportunities for transnational (TNA) and virtual access (VA) to European research infrastructures for researchers from the academic and private sector in this RICH Europe leaflet. Access the database on TNA and VA open calls here. The database can be filtered on scientific domain, the status of th... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
